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them remain in CCR with a median tollow-up
19,5 months (range 1 to 96 months) and 66%
probability ot 8-year EFS.
Conclusions:
1. In ehildren with ALL the FTBI-12Gy-
eontaining regimen is well tolerated
without the lite-threatening toxie
eomplieations.
2. FTBI-12Gy-eontaining regimen demon-
strates very good antileukemie efficacy tor
HR-ALL in I CR, but only Iimited tor ALL in
liCA.
3. 3. In context ot good tolerance ot FTBI in
atotal dose ot 12 Gy and its Iimited
antileukemie efficacy in ehildren with ALL
in II CR the escalation ot FTBI total dose
trom 12 Gy to 13,2 Gy appears to be
justitied in those children. Suppońed by
grant KBN 4 P05E 108 18.
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In loeally advaneed inoperable NSCLC
radiotherapy has traditionally been considered
the mainstay of treatmenł. Unfortunately, in most
instances this method does not allow for
eradication ot bulky tumor in the thorax and does
not prevent uncontrolled systemie disease. In
consequence the prognosis of these patients is
dismai and has remained essentially unchanged
within the last decades. The five-year survival
rates after irradiation varies between 3 and 10%.
During the last decades several approaches have
been tested to improve this outcome. Of those,
particular attention has toeused on combining
chemotherapy and radiation. Two most trequently
used strategies have included induetion
ehemotherapy folIowed by radiation, or
eoncurrent ehemoradiation. The results of a few
phase III triais comparing radiation alone with
radiation supplemented by chemotherapy have
demonstrated modest yet signifieant survival
benefit from the combined approach. Two recent
studies suggested that coneomitant
ehemoradiation might be more effeetive than
Rep. Pract. Oncol. Radiother. 6 (1) 2001
ehemotherapy preceding radiation. The gain
from the eoneurrent use ot both modalities
should however be weighted against inereased
toxicity. Further studies built upon recent
positive results should toeus on identifying
means of optimal interaetions between the two
modalities. This research should define the most
effeetive types and doses of antieancer agents
as well as the optimal teatures ot radiotherapy.
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SURGERY: IS IT STILL A PLACE FOR
RADIO-OR CHEMOTHERAPY?
P. van Houtte
Institut Jules Bordet, Brussels, Belgium
The two metaanalysis conducted by the
Cambridge group has cent the seene for
adjuvant treatment as well as the pattem of
failure analysis after surgery. In the pattem of
failure analysis peńormed after a complete
resection, local failure is a race event for
pathologieal stage 1 and II disease (less than 10
%). In opposite, for stage III, local tailure
remains an issue due to the wide range ot tumor
extent, from reseetable disease to unresectable
tumor. In eontrast, distant metastasis is a
common problem with figures ranging from 20 to
50%. A last issue is eertainly the problem ot
second cancer induced by a long history of
tobaeeo smoking rising the question of
chemoprevention.
To prevent distant metastasis, a systemie
treatment is the logical answer. The
metaanalysis suggested a slight nonsignificant
benefit for a sequential Cisplatine based
chemotherapy. The recent American trial of
Keller et al comparing postoperative
radiotherapy to a eombined ehemo-radiotherapy
approaeh did not showed any differenee for
stage III disease: the only important prognostic
tactor was the type ot mediastinal exploration:
sampling vs. radical disseetion. Several triais
are on going worldwide: Anita, ALPI, and lALT...
The main characteristics of those triais are to
include a cisplatine based chemotherapy
program and a large number ot patients. This
implies necessary a low efficacy; a smali
differenee is expeeted. Furthermore, the already
published triais showed a low eompliance to
chemotherapy.
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Is the page turned tor radiotherapy in a
combined approach with surgery? In view ot the
available randomized triais and the recent
metaanalysis, a quick answer is yes. Indeed,
both observed either no effect ar even a
detrimental impact on survival. Nevertheless,
those triais were performed during the last three
decades, a period ot many improvements in the
knowledge ot the disease, in imaging procedure,
in surgery and in radiotherapy. Preoperative
radiotherapy may increase the resectability rate
in well-selected patienł: same groups are still
advocating this approach tor superior sulcus
tumor whereas many phase II and same phase
III triais are combining radiation with
chemotherapy in a preoperative settings. The
data available suggested a higher rate ot
pathological complete response but also a slight
increase in morbidity. In contrast, postoperative
irradiation improves the local control especially
tor stage III disease: this was clearly
demonstrated by the Lung Cancer Study group
trial, the MRC trial and the Feng tria!.
Furthermore, we should remember that the
PORT metaanalysis suggested a differential
impact according to the tumor extenł: the
negative impact ot postoperative radiation
disappeared tor stage III disease (a similar
observation was made by Oautzenberg et al).
One possible explanation is that the therapeutic
effect ot postoperative radiotherapy
compensated the negative impact due to a poor
radiation technique (Iarge volume, high daily
dose, and cobalt machines...). Both approaches
imply to use a modern radiation technique
minimizing the risk ot inducing severe lite-
threatening late ettects: this is especially the
case for postoperative radiotherapy due to the
already loss ot lung tunction due to the surgery
and a long history ot tobacco abuse. This is
probably the place for aconformal
radiotherapeutic approach.
The last issue concerns the management of
patients after induction chemotherapy fol/owed
by surgery: the current approach is to reserve
postoperative radiotherapy for incomplete
resection or tor persistent nodal disease.
Probably, another important tactor may be the
presence ar not of nodal capsular rupture. We
are certainly lacking good data on the
postresection management and outcome of
those patients.
In conclusion, radiation has stil! its place tor
stage III disease in a combined approach with
surgery and chemotherapy providing the use ot
an adequate radiation technique.
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BREAST CANCER: IMPLlCATIONS
FORTHERAPY
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The data from over 3000 breast cancer
patients treated without adjuvant chemotherapy
and fol/owed-up for over 15 years were studied
with two aims:
1) to analyze the relationship between tumor
diameter and incidence ot distant
metastases during the 25 years after initial
treatment. The threshold volume at which
dissemination occurs can be estimated in
each subset ot patients and varies widely; it
is inversely correlated with the histologie
grade and the number of involved axil/ary
nodes.
2) to investigate the impact ot a residual tumor
on distant dissemination. In patients with
local recurrence, the incidence ot distant
dissemination is elevated. The analysis ot
the delay between the initial treatment and
clinical emergence of the metastases shows
that the excess ot metastases corresponds
to disseminations which are initiated after
initial treatment and theretore originated
from the residual tumor.
This conclusion was supported by the update
of s control/ed clinical trial comparing two
adjuvant treatments: A) a chemotherapy by
CMF or B) post-operative radiotherapy (RT)
tollowed by immunothcrapy with poły A - poly U.
At 15 years the cumulative incidence ot local
recurrence and of distant metastases is
significantly lower in the B group (42%
metastasis-tree survival in the RT group and
29% in the CT group p=0.03). This result seems
to be due mostly to lower incidence of local
recurrence.
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